| __timestamp | Amgen Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4699000000 | 35942000 |
| Thursday, January 1, 2015 | 4846000000 | 40028000 |
| Friday, January 1, 2016 | 5062000000 | 45853000 |
| Sunday, January 1, 2017 | 4870000000 | 53816000 |
| Monday, January 1, 2018 | 5332000000 | 60804000 |
| Tuesday, January 1, 2019 | 5150000000 | 77252000 |
| Wednesday, January 1, 2020 | 5730000000 | 45736000 |
| Friday, January 1, 2021 | 5368000000 | 50323000 |
| Saturday, January 1, 2022 | 5414000000 | 143526000 |
| Sunday, January 1, 2023 | 6179000000 | 149182000 |
| Monday, January 1, 2024 | 7096000000 | 154335000 |
Cracking the code
In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, Amgen Inc. and Halozyme Therapeutics, Inc. have showcased contrasting strategies in managing Selling, General, and Administrative (SG&A) expenses. Amgen, a biotech giant, consistently reported SG&A expenses averaging around $5.3 billion annually, peaking at $6.2 billion in 2023. This reflects a steady growth of approximately 31% from 2014. In contrast, Halozyme, a smaller player, saw its SG&A expenses rise by over 300%, from $35.9 million in 2014 to $149.2 million in 2023. This dramatic increase underscores Halozyme's aggressive expansion and investment in operational capabilities. The data highlights the diverse approaches these companies take in navigating the competitive biotech sector, with Amgen focusing on sustained growth and Halozyme on rapid scaling.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Exelixis, Inc.
Breaking Down SG&A Expenses: Amgen Inc. vs Viking Therapeutics, Inc.
Breaking Down SG&A Expenses: Amgen Inc. vs Merus N.V.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Amgen Inc. and Agios Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc. or Halozyme Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Grifols, S.A.
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Verona Pharma plc
Halozyme Therapeutics, Inc. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or MannKind Corporation